NEXPHORIA
Retatrutide
Triple GIP/GLP-1/glucagon receptor agonist. Advanced metabolic research compound.
Purchase Type
Fresh cold-chain delivery every 30 days
Format
For Research Use Only — Not For Human Consumption
This compound is sold exclusively for qualified research purposes. Not approved by the FDA for therapeutic use.
Retatrutide (LY3437943) is a next-generation triagonist peptide simultaneously activating GIP receptor (GIPR), GLP-1 receptor (GLP-1R), and glucagon receptor (GCGR). Developed by Eli Lilly, it represents the leading edge of the incretin-based therapeutic pipeline. The addition of glucagon receptor agonism to the dual incretin profile aims to enhance energy expenditure and hepatic fat mobilization beyond what dual agonists achieve.
Complete Your Protocol
Related compounds.
Side-by-Side Analysis
Compare Retatrutide with Similar Compounds
View purity, MW, storage, and pricing side by side.
Frequently Bought Together
Complete Your Protocol
Researchers commonly order these compounds together. Convenient multi-compound ordering.
Weight Management
This itemRetatrutide
10mg
$210
Weight Management
RecommendedAOD-9604
5mg
$53
Weight Management
Tirzepatide
10mg
$120
3 items selected
Uncheck any item to customize your bundle. Discount applied automatically at checkout.
Research Journal
Related Research Articles
GLP-1 Agonists and Appetite Regulation: Hypothalamic Circuits, Ghrelin, and Hunger Endpoint Study Design
A mechanistic deep dive into how GLP-1 agonists suppress appetite through hypothalamic ARC/VMH circuits, ghrelin/GLP-1 axis interplay, gastric emptying, and reward pathway modulation — with validated hunger endpoints and study design for preclinical metabolic research.
Retatrutide: Hepatic, Cardiac, and CNS Mechanisms Beyond Weight Loss
A deep dive into retatrutide's triple GLP-1R/GIPR/GCGR agonism effects on liver fat, cardiovascular endpoints, and brain circuits — mechanisms that extend far beyond the Phase 2 weight-loss headline data.
GLP-1 Agonist Discontinuation: Rebound Pharmacology, Washout Design, and Re-initiation Research Protocols
A comprehensive research guide covering the biological mechanisms of weight regain after GLP-1 agonist discontinuation, published clinical and preclinical rebound data, optimized washout period design, and re-initiation protocol strategies for researchers.
Complete Your Protocol
Metabolic Research Stack
Retatrutide's triple receptor activity and AOD-9604's lipolytic mechanism cover distinct and complementary aspects of adipose tissue research.
Weight Management
Retatrutide
10mg
$210
Weight Management
AOD-9604
5mg
$53